Trends in Cancer

Article	Citations
Subscription & copyright page	276
FBXW10: a male-biased E3 ligase in liver cancer	208
Revumenib: a new era in acute leukemia treatment	167
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	161
Engineering growth factor ligands and receptors for therapeutic innovation	151
Tumor-resident microbes: the new kids on the microenvironment block	142
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	139
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	134
Advisory Board and Contents	131
Subscription & copyright page	122
Subscription and copyright page	118
Radiotherapy and immunotherapy: open questions and future strategies	113
Navigating life as an early career researcher	110
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	106
Leveraging circulating microbial DNA for early cancer detection	103
Onco-condensates: formation, multi-component organization, and biological functions	103
Engine shutdown: migrastatic strategies and prevention of metastases	103
Accessing the vasculature in cancer: revising an old hallmark	103
Benefits and opportunities of the transgenic Oncopig cancer model	102
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	101
Chromatin as an old and new anticancer target	98
Subscription & copyright page	97
IDH-Mutant Brain Tumors Hit the Achilles’ Heel of Macrophages with R-2-Hydroxyglutarate	93
Regulation of metastatic organotropism	91
Oncogenic competence: balancing mutations, cellular state, and microenvironment	91

Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	88
Crosstalk of T cells within the ovarian cancer microenvironment	85
Recent developments in myeloid immune modulation in cancer therapy	84
Diet, nutrient supply, and tumor immune responses	80
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	77
Chromosomal instability and aneuploidy as causes of cancer drug resistance	74
Gut microbiota – a double-edged sword in cancer immunotherapy	73
Advisory Board and Contents	73
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	66
Tumor immunology CRISPR screening: present, past, and future	64
GOT2 consider the tumor microenvironment	62
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	62
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	62
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer	61
Pannexin biology and emerging linkages to cancer	60
Cell death, therapeutics, and the immune response in cancer	60
Subscription & copyright page	59
Subscription & copyright page	58
Advisory Board and Contents	56
Advisory Board and Contents	56
β-Galactosylceramidase in cancer: friend or foe?	55
Scaling data toward pan-cancer foundation models	54
Palmitate paves the way to lung metastasis	53
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	53
Genetic immune escape in cancer: timing and implications for treatment	52
Cancer catecholamine conundrum	52
Insights on ErbB glycosylation – contributions to precision oncology	52
Inflammation: the incubator of the tumor microenvironment	51
The emerging field of oncolytic virus-based cancer immunotherapy	51
Clinical and translational relevance of intratumor heterogeneity	51
Advisory Board and Contents	50
Advisory Board and Contents	50
Advisory Board and Contents	47
Subscription and copyright page	47
Advisory Board and Contents	47
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	47
Updating cancer research with patient-focused networks	46
RHOA takes the RHOad less traveled to cancer	45
Advisory Board and Contents	45
Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges	45
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	44
Subscription & copyright page	42
Emerging mechanisms of telomerase reactivation in cancer	42
Circulating cell-free DNA-based multi-cancer early detection	41
Molecular and clinical insights into early-onset endometrial cancer	41
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	40
Modeling metastasis in mice: a closer look	39
Redefining precision cancer prevention to promote health equity	39
Stress granules and hormetic adaptation of cancer	39
B7-H3: a robust target for immunotherapy in prostate cancer	39

Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	39
Advisory Board and Contents	38
Leveraging space innovations for cancer breakthroughs on Earth	37
Advisory Board and Contents	37
Advisory Board and Contents	37
Dissecting liver tumor heterogeneity to improve health equity	36
Subscription & copyright page	36
Cross-dressing of dendritic cells strengthens antitumor immunity	36
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	36
Advisory Board and Contents	36
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises	35
A macrophage-neutrophil program drives mammary carcinogenesis	35
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	34
Neoantigen-directed therapeutics in the clinic: where are we?	34
Immune response and inflammation in cancer health disparities	34
Functional heterogeneity of fibroblasts in primary tumors and metastases	34
Subscription & copyright page	33
A tipping point in cancer epidemiology: embracing a life course exposomic framework	33
Advisory Board and Contents	33
Space in cancer biology: its role and implications	32
Engineered bacterial therapeutics for detecting and treating CRC	32
Cancer cell adaptability: turning ribonucleoprotein granules into targets	31
Advisory Board and Contents	31
Ferroptosis vulnerability in FLT3-mutant leukemia	31
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	30
Epigenetic basis and targeting of cancer metastasis	29
Clonal evolution and hierarchy in myeloid malignancies	29
Subscription & copyright page	29
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	29
Advisory Board and Contents	29
Targeting the Mevalonate Pathway in Cancer	29
N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA	29
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Addressing the genetic/nongenetic duality in cancer with systems biology	28
Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic	27
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	27
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	26
Next-generation immunotherapies for brain metastatic cancers	25
Next-generation cancer vaccines and emerging immunotherapy combinations	24
Immunomodulation by endothelial cells: prospects for cancer therapy	24
NETscape or NEThance: tailoring anti-cancer therapy	24
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	24
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	24
Genitourinary cancer neoadjuvant therapies: current and future approaches	23
Lifileucel: the first cellular therapy approved for solid tumours	23
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	23
Successfully targeting the cancer system with metronomics for medulloblastoma	23
How cancer cells make and respond to interferon-I	22
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	22
Deciphering the roles of ABCB5 in normal and cancer cells	22
Future perspectives on engineered T cells for cancer	22
Embracing diversity: macrophage complexity in cancer	22
Tissue architecture in tumor initiation and progression	22
Subscription & copyright page	22
GSDME: A Potential Ally in Cancer Detection and Treatment	21
Persisting cancer cells are different from bacterial persisters	21
Poised epigenetic states dictate metastatic fitness	20
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	20
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	20
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	20
TET2, tumor control, and CAR T cell hyperproliferation	20
Subscription & copyright page	20
Hypoxia orchestrates the lymphovascular–immune ensemble in cancer	20
Zebrafish as a New Model to Study the Crosstalk between Tumor and Host Metabolism	20
New York’s Polyethnic-1000: a regional initiative to understand how diverse ancestries influence the risk, progression, and treatment of cancers	19
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity	19
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	19
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy	19
Enhancing dendritic cells by inhibiting BCL2	18
Defining obesity in the context of cancer: thinking beyond body mass index	18
Emerging and extensive clonal evolution in the pancreas	18
The clinical landscape of CAR-engineered unconventional T cells	18
Nanomedicine-based strategies to target and modulate the tumor microenvironment	18
Acetylation: a new target for protein degradation in cancer	18
Extracellular vesicle lipids in cancer immunoevasion	17
Revisiting the HIF switch in the tumor and its immune microenvironment	17
Every patient	17
Tackling PARP inhibitor resistance	17

Think zebras: challenges and opportunities for treating rare cancers	17
Advisory Board and Contents	17
Targeting ferroptosis in pancreatic cancer: a double-edged sword	17
Advisory Board and Contents	17
Subscription & copyright page	17
Interferon epsilon and ovarian cancer	16
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence	16
Intracranial CAR-T cell delivery in glioblastoma patients	16
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells	16
Tackling the next decade of cancer research	16
Subscription & copyright page	16
Current landscape of CD3 bispecific antibodies in hematologic malignancies	15
Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges	15
Tissue mechanics in tumor heterogeneity and aggression	15
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	15
Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy	15
Exploiting T cell signaling to optimize engineered T cell therapies	15
Dynamic immune signatures as biomarkers for irAEs	15
Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment	15
The tumor-draining lymph node as a reservoir for systemic immune surveillance	15
Hypertranscription and replication stress in cancer	15
Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma	14
Synovial Sarcoma Oncogenesis Revealed by Single-Cell Profiling	14
Lifestyle and host determinants of antitumor immunity and cancer health disparities	14
A novel transcriptomic-based classifier for senescent cancer cells	14
Subscription & copyright page	14
Translational Control of Immune Evasion in Cancer	13
Targeting phagocytosis to enhance antitumor immunity	13
Limited dsRNA editing impedes leukemia stem cells	13
Adaptive inhibition of CGAS signaling by TREX1	13
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy	13
Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma	13
Wargaming cancer: a strategy for future precision oncology?	13
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency	13
Spatial promoter–enhancer hubs in cancer: organization, regulation, and function	13
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer	13
Retrotransposons: Jump to Cancer?	13
Modeling tumor plasticity in organoid models of human cancer	13
Advisory Board and Contents	13
Ancestry-defined molecular taxonomy of prostate cancer	12
KRAS inhibitors: resistance drivers and combinatorial strategies	12
Impact of tissue-agnostic approvals on management of primary brain tumors	12
Into the era of mycobiome-driven cancer research	12
To Vaccinate or not: Influenza Virus and Lung Cancer Progression	12
On the path to equity in cancer research and care	12
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	12
Subscription & copyright page	12
Reductive stress in cancer: coming out of the shadows	12
Subscription & copyright page	12
Label-free optical imaging for brain cancer assessment	12
Myeloid cell path to malignancy: insights into liver cancer	11
State-matched organoid models to fight pancreatic cancer	11
Advisory Board and Contents	11
The peritumor microenvironment: physics and immunity	11
Subscription & copyright page	11
Subscription & copyright page	11
How Comorbidities Shape Cancer Biology and Survival	11
Advances in targeting RNA modifications for anticancer therapy	11
Advisory Board and Contents	11
Necroptosis and tumor progression	11
Emerging roles of nucleotide metabolism in cancer	10
Metabolic landscape of disseminated cancer dormancy	10
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	10
Drug independence and the curability of cancer by combination chemotherapy	10
Advisory Board and Contents	10
Epigenetic control of immunoevasion in cancer stem cells	10
Immunometabolism of CD8+ T cell differentiation in cancer	10
Immune organoids: from tumor modeling to precision oncology	10
Neuro-immune interactions and immuno-oncology	10
Low tumor mutational burden and immunotherapy in gliomas	9
Diversity upon diversity: linking DNA double-strand break repair to blood cancer health disparities	9
Plastic persisters: revival stem cells in colorectal cancer	9
An epigenetic signature in CD19-CAR T cells predicts clinical outcome	9
Trends in cancer imaging	9
Cancer fitness genes: emerging therapeutic targets for metastasis	9
Subscription and copyright page	9
Advisory Board and Contents	9
EZHIP’s role in diffuse midline glioma: echoes of oncohistones?	9
Building Diverse Mentoring Networks that Transcend Boundaries in Cancer Research	9
Optimizing the future: how mathematical models inform treatment schedules for cancer	9
Advisory Board and Contents	9
Generation of tumor neoantigens by RNA splicing perturbation	9
The future of cancer research: invest now	9
Targeting cancer stem cells in multiple myeloma	9
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy	8
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy	8
Neuronal and tumourigenic boundaries of glioblastoma plasticity	8
Immune mechanisms of toxicity from checkpoint inhibitors	8
Immune cells in residual disease and recurrence	8
Tweak to Treat: Reprograming Bacteria for Cancer Treatment	8
CD4+ T cells in antitumor immunity	8
Therapeutic targeting of regulatory T cells in cancer	8
Advisory Board and Contents	7
Anxiolytics cause anxiety in pancreatic cancer	7
Asparagine, a Key Metabolite in Cellular Response to Mitochondrial Dysfunction	7